PANACEA BIOTEC LTD Q1 RESULTS
![Mankind trumps EQT-ADIA to buy BSV for $1.67 bn](https://img.etimg.com/thumb/msid-112011217,width-100,height-75,resizemode-4/industry/healthcare/biotech/pharmaceuticals/mankind-pharma-trumps-eqt-adia-set-to-acquire-bsv-for-1-6-billion.jpg)
Mankind trumps EQT-ADIA to buy BSV for $1.67 bn
This is the largest acquisition by Mankind Pharma, India’s 4th largest pharma company by market share. A formal announcement regarding the deal is likely by this week.
![Mankind Pharma competes with EQT-ADIA combo for Rs 14,000 cr buyout of BSV Group from Advent](https://img.etimg.com/thumb/msid-111804993,width-100,height-75,resizemode-4/industry/healthcare/biotech/pharmaceuticals/mankind-pharma-competes-with-eqt-adia-combo-for-rs-14000-cr-buyout-of-bsv-group-from-advent.jpg)
Mankind Pharma competes with EQT-ADIA combo for Rs 14,000 cr buyout of BSV Group from Advent
The buyout of BSV Group (formerly Bharat Serum & Vaccines Ltd) is contested by Mankind Pharma and EQT with ADIA, each offering around Rs 14,000 crore ($1.6 billion). This acquisition, one of India's largest pharma buyouts, will significantly impact the domestic market and mark a successful exit for Advent International.
![Q3 results today: Hindalco Industries, BHEL, IRCTC among 500 companies to announce earnings](https://img.etimg.com/thumb/msid-107643859,width-100,height-75,resizemode-4/markets/stocks/earnings/q3-results-today-hindalco-industries-bhel-irctc-among-500-companies-to-announce-earnings.jpg)
Q3 results today: Hindalco Industries, BHEL, IRCTC among 500 companies to announce earnings
On Monday, over 299 companies announced their December quarter earnings which included the likes of NHPC, Coal India, 63 Moons Technologies, Allcargo Logistics, Balmer Lawrie Investments and Galaxy Surfactants.
![ETMarkets Smart Talk-Shiv Sehgal of Nuvama explains why he calls India’s investment thesis as 5D advantage](https://img.etimg.com/thumb/msid-102563840,width-100,height-75,resizemode-4/markets/expert-view/etmarkets-smart-talk-shiv-sehgal-of-nuvama-explains-why-he-calls-indias-investment-thesis-as-5d-advantage.jpg)
ETMarkets Smart Talk-Shiv Sehgal of Nuvama explains why he calls India’s investment thesis as 5D advantage
Nothing Fitch says is wrong, but nothing it says is new either and there aren’t any real-world implications of the downgrade (as far as covenants being tripped or people not being able to own Treasuries).
![Top Businessmen India lost in 2022: From Rakesh Jhunjhunwala to Cyrus Mistry, these billionaires left the world](https://img.etimg.com/thumb/msid-96591574,width-100,height-75,resizemode-4/news/new-updates/top-businessmen-india-lost-in-2022-from-rakesh-jhunjhunwala-to-cyrus-mistry-these-billionaires-left-the-world.jpg)
Top Businessmen India lost in 2022: From Rakesh Jhunjhunwala to Cyrus Mistry, these billionaires left the world
The sudden demise of several billionaires in 2022 also shook the Indian industry. The list includes the names of 11 billionaires including Rakesh Jhunjhanwala and Cyrus Mistry.
![Ahead of Market: 10 things that will decide D-Street action on Wednesday](https://img.etimg.com/thumb/msid-94794295,width-100,height-75,resizemode-4/markets/stocks/news/ahead-of-market-10-things-that-will-decide-d-street-action-on-wednesday.jpg)
Ahead of Market: 10 things that will decide D-Street action on Wednesday
Momentum indicator Moving Average Convergence Divergence (MACD) showed a bullish trade setup on the counters of Axis Bank, Morepen Labs, M&M Financial Services, Panacea Biotec, Heidelberg Cement and JMC Projects.
- Go To Page 1
Stocks in the news: TCS, Delta Corp, Axis Bank, Infosys, Bajaj Auto and Adani Ports
Delta Corp, GM Breweries, Trident Texofab, Supreme Infrastructure, Gujarat Hotels and Choksi Imaging are among the companies that will announce their results for September 2022 quarter today.
Stocks in the news: TCS, HCL Tech, HDFC, Tata Motors, HUL and Ambuja Cements
Tata Group's IT major Tata Consultancy Services, will officially kick-off earning season of India Inc. It will announce its results for the quarter ended September 30, 2022.
Cipla gains despite YoY fall in Q3 profit as bottom-line surpasses estimates
Cipla reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021. An ET NOW poll of analysts had estimated the net profit at Rs 710 crore.
Cipla Q3 results: Net profit slips marginally to Rs 729 crore, beats estimates
Total revenue from operations was at Rs 5,478.86 crore against ET NOW poll of Rs 5,420 crore.
Panacea arm defaults; lenders may extend repayment date
Panacea Biotec Pharma, a 100% subsidiary of Sputnik V Covid jab manufacturer Panacea Biotec, defaulted on payment of ₹114.67 crore including an interest component due on September 30.
Cipla Q2 results: Net profit rises 8% to Rs 712 cr; meets D-Street estimate
Revenues for the quarter rose 10.3 per cent YoY to Rs 5,485.84 crore compared with Rs 4,972.58 crore in the same quarter last year.
Biggest gainers & losers of the day: Housing financiers roar; Vodafone Idea tanks 19%
IIFL Wealth management saw a robust demand after record results, followed by a strong buying interest in housing finance firms. However, Vodafone Idea continued to bleed for a second straight day.
Biggest gainers & losers of the day: Century Textiles shines, beverage stocks fall
Selling pressure in banking and financial players dragged the markets lower as investors awaited the Fed meet’s outcome scheduled later in the day. Jitters over Chinese clampdown on tech firms, too, dampened the sentiments.
Panacea Biotec posts loss of Rs 54 cr in Q4
Shares of Panacea Biotec closed at Rs 415.30 per scrip on BSE, up 0.12 percent from its previous close.
Stocks in news: ITC, Infosys, PVR, MTAR Tech, SBI, Panacea Biotec and Radico Khaitan
Panacea Biotec, NRB Bearings, Dhunseri Ventures, Lyka Labs, Jenburkt Pharmaceuticals and Burnpur Cement are among companies that will announce their March quarter results today.
Cadila Healthcare Ltd may soon start human trials of vaccine
At a recent meeting at the Central Drugs Standard Control Organisation (CDSCO)-the regulatory authority of India, subject experts recommended the Drug Controller General of India (DCGI) to grant permission to the company for starting human trials.
Stocks in the news: HDFC Bank, M&M, Omaxe, TCS, Panacea Biotec and Hotel Leelaventure
Omaxe promoter entity Guild Builders has been restricted from further pledging of its shares.
After Hours: Future Consumer on fire; Unitech hits upper circuit
The recovery in the market comes at a crucial time as the much-awaited Gujarat polls kick starts on Saturday.
Sensex, Nifty inch up ahead of Q2 earnings season
Earnings growth for Q2 is likely to be subdued but on a QoQ basis it will be better.
Panacea Biotec slips as Q1 net loss widens to Rs 37 crore
Panacea Biotec Ltd slipped as much as 9.89 per cent in trade on Friday, after the company a standalone net loss of Rs 36.90 crore.
Panacea Biotec Q1 net loss at Rs 37 crore
Drug firm Panacea Biotec today reported a standalone net loss of Rs 36.90 crore for the quarter ended June 30, 2015.
Panacea Biotec Q3 net profit at Rs 83 crore
Panacea Biotec today posted a net profit of Rs 82.79 crore for the third quarter ended December 31, 2013.
Panacea Biotec Q2 net loss at Rs 56 crore
Panacea Biotec today reported a net loss of Rs 56.27 crore for the second quarter ended September 30.
Panacea Biotec posts net loss at Rs 66 crore in Q1
Panacea Biotec today posted a net loss of Rs 65.97 crore for the first quarter ended June 30, 2012.
Panacea Biotec Q1 net dips 48.63 pc to Rs 16.72 cr
Panacea Biotec today said its net profit declined by 48.63 per cent to Rs 16.72 crore for the quarter ended June 30, 2011 over the same period previous fiscal.
Panacea Biotec Q4 net dips 25.19% to Rs 43.03 cr
Panacea Biotec Ltd today said its net profit has declined by 25.19% to Rs 43.03 crore for the fourth quarter ended March 31, 2011.
Panacea Biotec Q3 net up over five-fold to Rs 42.60 cr
Panacea Biotec today said its net profit zoomed over five-fold to Rs 42.60 crore for the third quarter ended December 31, 2010, over the same period previous fiscal.
Panacea Biotec Q3 net up nearly six fold to Rs 42.6 cr
The company had posted a net profit of Rs 7.34 crore for the same quarter previous fiscal, Panacea Biotec said in a filing to the Bombay Stock Exchange (BSE).
Load More